Erbitux filed for first-line head and neck cancer in US
This article was originally published in Scrip
Executive Summary
ImClone Systemshas filed an application with the US FDAto broaden the use of its EGFR-targeted monoclonal antibody drug Erbitux (cetuximab) to include the first-line treatment of patients with recurrent and/or metastatic head and neck cancer in combination with chemotherapy.